Home
Services
Digital
Technology
RFP Builder
News
About
Careers
Giving
Services
Digital
Technology
RFP Builder
Careers
About us
Get in touch

FIECON at ISPOR US

May 6-8 Atlanta, GA, USA

Our expert talk about Generalized Cost-Effectiveness Analysis

On Monday, May 6 11:30am to 12:30pm, ISPOR attendees met Peter Kolchinsky, author of "The Great American Drug Deal”, founder of RA Capital and board member of No Patient Left Behind at the FIECON booth.
Peter is a staunch advocate for the Biotech Social Contract and Generalized Cost-Effectiveness Analysis (GCEA). Please check out the video to hear how the cost-effectiveness landscape is evolving in the US, through growing adoption of GCEA by investors and the industry.
Watch recording
About Peter

Our latest service innovations

Early value assessment for pipeline optimization
Whether you're considering self-funded launches or out-licensing, our model provides comprehensive simulations of potential benefits, enhancing your strategic decision-making process in commercialization.
Find out more
AI-assisted systematic literature reviews (SLRs)
Our real-time interactive dashboard covers your regular needs for summarizing extracted data from analyzed publications, automatically updating as new research is added.
Find out more
PICOS prediction for HTA/payer scoping
We offer an advanced value communication tool that allows you to dynamically create custom scenarios, maximizes the efficiency and guarantees highly engaging meetings with the payers.
Find out more
Explore a demo of our FIECON Modelling Center
Modelling Center is a repository of hosted, Excel-based economic models and value evidence, focused on ensuring global payer engagement and optimal patient access.
Find out more
Get transparent pricing using our RFP builder!
Input top line project details and select the deliverable of interest and you'll receive a ballpark quote immediately, no commitment necessary! Our RFP Builder is the dawn of a new era in HEOR pricing transparency
Explore our pricing
Rapid scientific advice
We provide fast, flexible, and affordable solutions by asking open-ended questions based on the critique of clinical trial programs and economic models.
Find out more

Our team

We had a team of FIECON experts available to discuss our products and services at stand #913 in the main exhibition hall.
Mark Fisher
Chief Operating Officer
Talk to Mark about:
  • HEOR and HTA strategy
  • Rapid Scientific Advice
  • Early Value and Pipeline Assessment
Karl Freemyer
Head of Business Development
Talk to Karl about:
  • AI-assisted SLRs
  • Digital Modelling Dashboards
  • PICOs Prediction for Joint Clinical Assessment
Susan Suponcic
Strategic Council member
Talk to Susan about:
  • US and Global Product Launch Strategy
  • Strategic and Tactical Pricing Initiatives
  • Portfolio Investment Optimisation
Andrew Revel
Director of Business Development
Talk to Andrew about:
  • HEOR and Market Access Solutions
  • Partnership Strategies
  • Early Value Assessment of Assets
Sam Nam
Director of Business Development
Talk to Sam about:
  • Market Access Hub
  • AI-assisted literature review
  • RFP Builder
Alex Eddy
Manager, HEOR and Access
Talk to Alex about:
  • Global and Local Cost-Effectiveness Models
  • Budget Impact Models
  • HTA Submission Strategies

Our Research & Posters

We will be presenting on 4 research topics this year, including a review of ICER assessments which seeks to understand the extent to which product list price in the US is the key driver of cost effectiveness ratios in ICER assessments.
Two of our posters have been identified in the top 5% of research submitted to the conference and finalists for the ISPOR 2024 Research Presentation Awards. Poster presenters will be available in person to talk about their research conclusions during the discussion periods.

Poster Session 1

Date: Monday, May 6
Poster session time: 10:30AM-1:30PM
Discussion period: 12:30PM-1:30PM
Top 5% Finalist
EE88: Cost-Effectiveness of Apixaban Compared to Warfarin, Dabigatran and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation: Results for High-Risk Patient Subgroups Based on the Aristophanes Real-World Evidence Study.
Read more
Top 5% Finalist
EE4: Should NICE Consider Adoption of a Societal Perspective? Comparison of the ICER 2023 Value Assessment Framework with the NICE 2022 Methods Guide.
Read more

Poster Session 4

Date: Tuesday, May 7
Poster session time: 3:30PM-6:30PM
Discussion period: 4:00PM-5:00PM
EE56: ICER vs NICE – What Are Your Key Considerations for Health Technology Assessments for Rare Disease Therapies? Insights from a Review of Completed Assessments (2017-PRESENT).
Read more

Poster Session 5

Date: Wednesday, May 8
Poster session time: 9:00AM-11:30AM
Discussion period: 9:00AM-10:00AM
EE527: Is List Price the Key Driver of ICER Assessments? Exploring Drivers of Cost-Effectiveness.
Read more

Get in touch

Get a completely free, no-obligation opportunity to discuss your needs and see how we can boost your business.
  • Brainstorm solutions to key challenges with experienced team
  • Validate your strategy and value evidence
  • Learn more about FIECON’s products and key areas of expertise and discuss opportunities for collaboration

Your contact details

I would like to
By submitting this form, you confirm that you agree to our website terms of use

Thank you!

We received your details. Someone from our team will contact you soon.
Oops!
Something went wrong while submitting the form.
About us
Services
Get in touch
Privacy Policy
Cookie Policy
Consent Preferences
© Fiecon 2024